Apollo Therapeutics

Biologics developed via academic-collaboration model

Privately held: no public share price · United Kingdom

Assets

(4 total)
4Total Assets
0Approved
0Phase 3 / Filed
4Phase 1–2 / Early
5Diseases
Quick filter:
Showing 4 of 4 assets
Target & Modality
Phase 2
ZIP12 (zinc transporter)Monoclonal antibody
Pulmonary Arterial Hypertension
Phase 2
IL-18Monoclonal antibody
Atopic Dermatitis
Phase 2
GLP-1 receptor; FGF21 receptorProtein / enzyme therapeutic
ObesityType 2 Diabetes
Phase 1
GCN2 (EIF2AK4)Small molecule
Acute Myeloid Leukemia

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
August 2027 (1)
APL-9796Phase 2Pulmonary Arterial Hypertension
Est. primary completion 2027-08-30 · NCT06846554 · CT.gov ↗
What to watch
October 2027 (1)
camoteskimabPhase 2Atopic Dermatitis, Atopic, Dermatitis, Dermatitis, Atopic, Dermatologic Disease, Eczema, Eczema Atopic Dermatitis, Eczema, Atopic
Est. primary completion 2027-10-31 · NCT07599813 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

16 September 2025Topline resultcamoteskimabPhase 2a CHAMELEON (NCT06436183) of camoteskimab in atopic dermatitis met its primary endpoint (EASI at week 16)

Financial reports

No financial reports recorded.